The Bursitis Treatment Market encompasses pharmaceutical, therapeutic, rehabilitative, and surgical approaches used to manage bursitis affecting joints such as the shoulder, hip, elbow, and knee. Treatment options include medications, physical therapy, surgery, and alternative therapies. According to a recent report by Wise Guys Report, the global market was valued at approximately USD 1.86 billion in 2024 and is expected to reach around USD 3.5 billion by 2035, representing a CAGR of approximately 5.9%.
Market expansion is being supported by increasing awareness of musculoskeletal disorders, an aging population, physical activity-related injuries, and improvements in treatment technologies. The growing preference for less invasive approaches and advances in rehabilitation and regenerative medicine are also influencing the future treatment landscape.
Market Drivers
Increasing Prevalence of Bursitis
Bursitis can develop in several joints and may be associated with repetitive movement, aging, physical activity, and other musculoskeletal factors. Growing recognition and diagnosis of the condition can increase demand for treatment services and therapies.
Growing Geriatric Population
Older adults are more likely to experience various musculoskeletal conditions. The expansion of the elderly population is therefore contributing to demand for pain-management, rehabilitation, and orthopedic care.
Rising Sports and Physical Activity
Increased participation in sports and physically demanding activities can contribute to repetitive joint stress and related conditions. Greater awareness among athletes and physically active individuals can support early treatment and rehabilitation.
Advancements in Minimally Invasive Treatment
Innovations in injection techniques, minimally invasive procedures, and regenerative approaches are creating new treatment possibilities. These approaches can help healthcare providers address bursitis while potentially reducing recovery requirements.
Increasing Awareness of Joint Health
Patients are becoming more aware of musculoskeletal health and chronic pain-management options. Greater access to health information and specialist care is encouraging individuals to seek professional evaluation.
Market Challenges
Treatment Costs
The cost of consultations, medications, physical therapy, imaging, injections, and surgical procedures can create affordability challenges for some patients.
Side Effects of Certain Medications
Pharmacological treatment can involve safety considerations depending on the medication and patient circumstances. These concerns can influence treatment selection and encourage the development of alternative approaches.
Competition from Non-Pharmaceutical Approaches
Physical therapy, rehabilitation, lifestyle modifications, and other non-drug approaches can compete with medication-based treatment. Healthcare providers may use multiple approaches depending on individual needs.
Limited Awareness in Developing Markets
Awareness of bursitis and available treatment options remains uneven across regions. Limited access to orthopedic specialists and rehabilitation facilities can restrict market development in some countries.
Browse In-depth Market Research Report on Bursitis Treatment Market:
Bursitis Treatment Market Report
Market Segmentation
By Treatment Type
Medications
Physical Therapy
Surgery
Alternative Therapies
The medications segment represents a major component of the market, supported by the widespread use of pharmacological approaches for pain and inflammation management.
By Application Area
Shoulder
Hip
Elbow
Knee
The shoulder represents a prominent application area, followed by the hip, elbow, and knee.
By End User
Hospitals
Orthopedic Clinics
Rehabilitation Centers
By Drug Class
Nonsteroidal Anti-Inflammatory Drugs
Corticosteroids
Analgesics
By Region
North America
Europe
Asia-Pacific
South America
Middle East & Africa
Regional Insights
North America
North America is the leading regional market, supported by advanced healthcare infrastructure, high awareness of musculoskeletal disorders, and strong access to orthopedic and rehabilitation services. WiseGuyReports valued the regional market at approximately USD 800 million in 2024 and projected it to reach USD 1.4 billion by 2035.
Europe
Europe is another significant market, supported by an aging population, established healthcare infrastructure, and growing awareness of chronic musculoskeletal conditions. Healthcare providers are increasingly emphasizing patient-centered pain management and rehabilitation.
Asia-Pacific
Asia-Pacific is expected to witness significant growth as healthcare access improves and awareness of joint health increases. Rising healthcare investment, expanding specialist services, and a large population base provide substantial opportunities.
South America
South America is expected to experience moderate growth as healthcare infrastructure develops and access to orthopedic treatment improves. Brazil and other major markets offer opportunities for pharmaceutical and healthcare providers.
Middle East & Africa
The Middle East and Africa are developing markets where improved healthcare facilities and greater awareness of musculoskeletal disorders can support future demand.
Key Players
Major companies identified in the Bursitis Treatment Market include Teva Pharmaceutical Industries, AstraZeneca, Mylan, AbbVie, Hikma Pharmaceuticals, GlaxoSmithKline, Sanofi, Roche, Amgen, Bristol Myers Squibb, Pfizer, Eli Lilly, Novartis, Merck & Co., and Johnson & Johnson.
Competition is centered on pharmaceutical innovation, treatment efficacy, product portfolios, strategic collaborations, and expansion into emerging healthcare markets.
Future Outlook
The Bursitis Treatment Market is positioned for continued expansion as the prevalence of musculoskeletal conditions increases and patients gain greater access to treatment. Pharmaceutical therapies are expected to remain important, while physical therapy, minimally invasive procedures, regenerative medicine, and other approaches are likely to diversify the treatment landscape.
Digital healthcare and telemedicine may also create opportunities for remote consultations, patient monitoring, and follow-up care. At the same time, pharmaceutical companies are likely to focus on developing therapies that provide effective symptom management while addressing safety and patient-comfort considerations.
Overall, the market is expected to benefit from rising awareness, an aging population, healthcare expenditure, and technological progress. WiseGuyReports projects the market to grow from approximately USD 1.97 billion in 2025 to USD 3.5 billion by 2035 at a CAGR of 5.9%.
Related Reports:
|
